CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Bortezomib +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00992446
NCT00992446Phase 2Completed
CompareCT.gov

Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen

Fred Hutchinson Cancer Center·interventional·Posted Oct 9, 2009·Updated Mar 18, 2020

In Brief

A Phase 2 clinical trial evaluating Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, and 6 other interventions for Adult Diffuse Large B-Cell Lymphoma and 5 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects and how well bortezomib and vorinostat work in treating patients with non-Hodgkin lymphoma (NHL) after patients' own stem cell (autologous) transplant. Bortezomib and vorinostat in the laboratory may stop the growth of lymphoma cells and make them more likely to die by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat after an autologous stem cell transplant may thus kill lymphoma cells that remain after transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 9, 2009
Enrollment StartSep 2, 2010
Primary CompletionJun 17, 2015
Study CompletionOct 29, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.7 years ago

Interventions

Autologous Hematopoietic Stem Cell Transplantationprocedure

Undergo ASCT

Bortezomibdrug

Given IV

Carmustinedrug

Given IV

Cytarabinedrug

Given IV

Etoposidedrug

Given IV

Melphalandrug

Given IV

Rituximabdrug

Given IV

Vorinostatdrug

Given PO